Products
Interferon beta-1b is commercially available as a powder and solvent for the preparation of a solution for injection (Betaferon). It has been approved in many countries since 1995.
Structure and properties
Interferon beta-1b is a recombinant protein of 165 amino acids with a molecular mass of approximately 18,500 Da. It is derived from an E. coli strain and, unlike interferonum beta-1a, is not glycosylated. It is therefore somewhat less similar to the natural protein than interferon beta-1a.
Effects
Interferon beta-1b (ATC L03AB08) has antiviral, antiproliferative, antitumor, and immunomodulatory properties. It slows disease progression, decreases the frequency of relapses, and reduces their severity.
Indications
For the treatment of multiple sclerosis.
Dosage
According to the SmPC. The injection solution is usually injected subcutaneously every other day. The injection site should be changed regularly.
Contraindications
- Hypersensitivity
- History of major depressive disorder and/or suicidal tendencies in patients
- Hepatic insufficiency
- Inadequately controlled epilepsy
Full precautions can be found in the drug label.
Interactions
Interferons are known to be CYP inhibitors. Corresponding drug-drug interactions are possible.
Adverse effects
The most common possible adverse effects include flu-like symptoms, headache, muscle pain, abdominal pain, elevated liver enzyme levels, blood count abnormalities, skin rash, urinary urgency, sleep disturbances, incoordination, and application site reactions. Interferons may rarely cause liver damage.